论文部分内容阅读
目的:观察恩度联合含铂类化疗方案治疗晚期非小细胞肺癌胸腔积液急性发作的临床疗效。方法:选择2014年3月至2016年1月在我院接受治疗的晚期非小细胞肺癌胸腔积液急性发作患者1 0 0例,按照随机抽签的方式将其分为观察组和对照组,对照组患者给予单纯的含铂类化疗,观察组则给予恩度联合含铂类化疗,治疗结束后,观察两组的临床疗效。结果:治疗后,观察组的总缓解率为88%、生活质量总改善率为82%,明显的高于对照组的总缓解率56%、总改善率4 4%,两组比较差异具有统计学意义(P<0.0 5);治疗后,观察组胸水V EG F、H I F-1α水平分别为(3 3 4.7±8 1.4)p g/m L、(4 2.7±3.9)n g/L明显的低于对照组胸水V EG F水平(4 5 1.7±9 3.2)p g/m L、HIF-1α水平(48.9±3.2)ng/L,且观察组的肿瘤标记物水平明显的低于对照组,两组比较差异具有统计学意义(P<0.05);观察组在治疗期间总共发生69人次不良反应,对照组总共发生68人次不良反应,两组比较无显著差异(P>0.05)。结论:恩度联合含铂类化疗方案治疗晚期非小细胞肺癌胸腔积液急性发作具有显著的临床效果,有效地降低患者胸水VEGF、HIF-1α水平,且不会增加不良反应的发生。
Objective: To observe the clinical efficacy of Endue combined with platinum-based chemotherapy in the treatment of acute episodes of pleural effusion in advanced non-small cell lung cancer. METHODS: One hundred and ten patients with acute episodes of pleural effusion in advanced non-small cell lung cancer who were treated in our hospital from March 2014 to January 2016 were selected and randomly divided into observation group and control group The patients were given pure platinum-containing chemotherapy, while the observation group was given Endo combined with platinum-containing chemotherapy. After the treatment, the clinical efficacy was observed. Results: After treatment, the total remission rate of the observation group was 88%, the total quality of life improvement rate was 82%, significantly higher than the control group 56% of the total remission rate, the overall improvement rate of 44%, the difference between the two groups with statistics (P <0.05). After treatment, the levels of VEGF and HI F-1α in the pleural effusion of the observation group were (3 3 4.7 ± 8 1.4) pg / m L and (4 2.7 ± 3.9) ng / L, respectively (P <0.05), and the level of HIF-1α (48.9 ± 3.2) ng / L in the pleural effusion of the control group was significantly lower than that of the control group The difference between the two groups was statistically significant (P <0.05). A total of 69 adverse reactions occurred in the observation group and 68 adverse reactions occurred in the control group. There was no significant difference between the two groups (P> 0.05). Conclusions: Endo combined with platinum-based chemotherapy for the treatment of acute episodes of pleural effusion in patients with advanced non-small cell lung cancer has a significant clinical effect, effectively reducing the levels of VEGF and HIF-1α in pleural effusion without increasing the incidence of adverse reactions.